Neurogene Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Neurogene Inc. (NGNE), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are NGNE insiders buying or selling?
In the last 12 months, Neurogene Inc. insiders reported 0 open-market purchases ($0) and 9 sales ($1.1M) — net selling of $1.1M. Since March 2018, Trabud has recorded 56 Form 4 filings for NGNE: 12 buys ($42.1M) and 44 sells ($1.9M).
Source: SEC EDGAR Form 4
Key Statistics (March 2018 – Jul 8, 2026)
Total Form 4 filings
56
SEC EDGAR
Insider filers
14
Insider buys (12)
$42.1M
Insider sells (44)
$1.9M
Insider sentiment
Net buyingNet insider flow of $40.2M in net buying since March 2018, and $1.1M in net selling over the last 12 months.
Recent NGNE insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Christine Mikail Cvijic | President and CFO | Sale | 4.8K | $36.12 | $173.4K | SEC ↗ |
| Jul 2, 2026 | Christine Mikail Cvijic | President and CFO | Sale | 4.8K | $34.71 | $166.6K | SEC ↗ |
| May 8, 2026 | Christine Mikail Cvijic | President and CFO | Sale | 9.6K | $31.25 | $300.0K | SEC ↗ |
| Mar 30, 2026 | Christine Mikail Cvijic | President and CFO | Sale | 2.6K | $21.62 | $55.3K | SEC ↗ |
| Mar 30, 2026 | McMinn Rachel | Chief Executive Officer | Sale | 3.4K | $22.07 | $74.0K | SEC ↗ |
| Mar 30, 2026 | Julie Jordan | Chief Medical Officer | Sale | 828 | $21.89 | $18.1K | SEC ↗ |
| Mar 17, 2026 | Stuart Cobb | Chief Scientific Officer | Sale | 6.8K | $20.81 | $141.4K | SEC ↗ |
| Mar 17, 2026 | Christine Mikail Cvijic | President and CFO | Sale | 4.0K | $20.81 | $84.2K | SEC ↗ |
| Mar 3, 2026 | Christine Mikail Cvijic | President and CFO | Sale | 4.8K | $25.11 | $120.5K | SEC ↗ |
| May 15, 2025 | Stuart Cobb | Chief Scientific Officer | Sale | 6.8K | $15.15 | $103.0K | SEC ↗ |
| Mar 17, 2025 | Christine Mikail Cvijic | President and CFO | Sale | 4.5K | $16.94 | $76.2K | SEC ↗ |
| Nov 27, 2024 | Srinivas Akkaraju | 10% Owner | Purchase | 48.8K | $25.83 | $1.3M | SEC ↗ |
| Nov 26, 2024 | Christine Mikail Cvijic | President and CFO | Purchase | 24.0K | $20.48 | $491.4K | SEC ↗ |
| Nov 26, 2024 | McMinn Rachel | Chief Executive Officer | Purchase | 47.5K | $20.40 | $969.0K | SEC ↗ |
| Aug 17, 2023 | Felix Baker | Director, 10% Owner | Purchase | 2.3M | $0.64 | $1.5M | SEC ↗ |
| Aug 14, 2023 | Sean Michael Smith | Interim CFO, Prin Acct Off | Sale | 1.3K | $0.62 | $818.14 | SEC ↗ |
| Apr 5, 2023 | Priti Patel | Other | Sale | 3.8K | $0.69 | $2.6K | SEC ↗ |
| Feb 3, 2023 | Sean Michael Smith | Principal Accounting Officer | Sale | 3.3K | $0.60 | $2.0K | SEC ↗ |
| Feb 3, 2023 | Priti Patel | Chief Medical Officer | Sale | 14.4K | $0.60 | $8.6K | SEC ↗ |
| Aug 12, 2022 | Sean Michael Smith | Principal Accounting Officer | Sale | 1.7K | $0.99 | $1.6K | SEC ↗ |
| May 3, 2022 | Priti Patel | Chief Medical Officer | Sale | 5.5K | $1.22 | $6.7K | SEC ↗ |
| Aug 26, 2021 | DRACHMAN JONATHAN G | President and CEO | Purchase | 150.0K | $6.22 | $933.5K | SEC ↗ |
| Jun 18, 2021 | Carl Walkey | Senior Vice President | Sale | 600 | $10.19 | $6.1K | SEC ↗ |
| Jun 11, 2021 | Carl Walkey | Senior Vice President | Sale | 650 | $10.82 | $7.0K | SEC ↗ |
| Jun 9, 2021 | Carl Walkey | Senior Vice President | Sale | 600 | $11.00 | $6.6K | SEC ↗ |
Showing the 25 most recent of 56 Form 4 filings for Neurogene Inc..
Most active NGNE insiders
- Carl Walkey24 filings
- Christine Mikail Cvijic8 filings
- Felix Baker4 filings
- DRACHMAN JONATHAN G4 filings
- Priti Patel3 filings
Ask anything about NGNE insider activity
Use Trabud's AI agent to query Neurogene Inc.'s Form 4 history in plain English — "Show me NGNE CEO purchases this year" or compare it against any other ticker.
Open the AI agentNGNE insider trading FAQ
Are Neurogene Inc. insiders buying or selling?
In the last 12 months, Neurogene Inc. insiders reported 0 open-market purchases ($0) and 9 sales ($1.1M) — net selling of $1.1M. Since March 2018, Trabud has recorded 56 Form 4 filings for NGNE: 12 buys ($42.1M) and 44 sells ($1.9M). Over the full record that is net buying of $40.2M.
How many insiders trade NGNE stock?
14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Neurogene Inc.. The most recent filing was accepted on Jul 8, 2026.
Where does Trabud get NGNE insider trading data?
All NGNE insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.